PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28395050
OWN - NLM
STAT- MEDLINE
DA  - 20170410
DCOM- 20170414
LR  - 20170414
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 147
IP  - 3
DP  - 2017 Mar 01
TI  - Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death.
PG  - 273-277
LID - 10.1093/ajcp/aqw212 [doi]
AB  - Objectives: To examine the relationship between the recently defined Gleason
      grade groups and prostate cancer-specific mortality. Methods: If the probability 
      of prostate cancer-specific death is symbolized as P(PSD), the probability of
      biochemical failure is symbolized as P(BF), and the probability of prostate
      cancer-specific death after biochemical failure is symbolized as P(PSD | BF),
      then the rules of probability provide a way to estimate P(PSD) as P(PSD) = P(PSD 
      | BF) * P(BF) Using this model and data from the literature for P(PSD | BF) and
      P(BF), I estimate here values of P(PSD) for the five newly described Gleason
      grade groups. Results: The expected probability of prostate cancer- specific
      death is closely related to the new Gleason grade groups and ranges from a low of
      0.014 for grade group 1 to a high of 0.15 for grade group 5. Conclusions:
      Although using the original study patient population may require years of
      additional follow-up to examine prostate cancer-specific mortality, the evidence 
      available now indicates that these new Gleason grade groups relate to prostate
      cancer-specific mortality.
FAU - Vollmer, Robin T
AU  - Vollmer RT
AD  - From the VA and Duke University Medical Centers, Durham, NC.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - AIM
SB  - IM
MH  - Humans
MH  - Male
MH  - *Models, Statistical
MH  - *Neoplasm Grading
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/blood/diagnosis/*mortality/*pathology
OTO - NOTNLM
OT  - Biochemical failure
OT  - Gleason grading
OT  - PSA
OT  - Prostate cancer
OT  - Prostate cancer-specific mortality
EDAT- 2017/04/11 06:00
MHDA- 2017/04/15 06:00
CRDT- 2017/04/11 06:00
AID - 3053465 [pii]
AID - 10.1093/ajcp/aqw212 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2017 Mar 1;147(3):273-277. doi: 10.1093/ajcp/aqw212.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>